期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Journal of Bone Oncology LetPub Score 5.9
50 ratings
Rate
Reputation 7.1 Influence 4.6 Speed 7.0 | ||||||||||||||||
期刊簡稱 | J BONE ONCOL | ||||||||||||||||
ISSN | 2212-1374 | ||||||||||||||||
h-index | N.A. | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 3.20%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | https://www.journals.elsevier.com/journal-of-bone-oncology | ||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/JBO | ||||||||||||||||
開放訪問 | Yes | ||||||||||||||||
出版商 | Elsevier GmbH | ||||||||||||||||
主題領域 | Medicine | ||||||||||||||||
出版國/地區 | Germany | ||||||||||||||||
發行頻率 | |||||||||||||||||
創刊年 | 0 | ||||||||||||||||
每年文章數 | 47每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 96.61% | ||||||||||||||||
OA Related Info | APC: Yes( USD2320; ) APC waiver:Check Notes Other charges: No Keywords: bone oncology、cancer、cancer treatment、radiotherapy、surgery、pharmacology Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q2
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2212-1374%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 20 Weeks | ||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Journal of Bone Oncology] 的評論 | 撰寫評論 |
作者: Berton BurneJones 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-06-21 09:05:38 評論於 Review speed: 1.0 | Submission hit rate: 25.0 Emphasis on research direction: bone tumors Sharing experience: Quarterly, too little published, very difficult(0) 讚! | Berton BurneJones |
作者: 风见沛桃 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-09-05 21:26:53 評論於 Meta analysis? Is there a review article? I would like to read it(0) 讚! | 风见沛桃 |
作者: 風見浩岚 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-07-05 21:59:58 評論於 This year, I hit a three-pointer, 3.066(0) 讚! | 風見浩岚 |
作者: 润发大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-10-30 21:32:12 評論於 However, if it falls out of the top three tiers, the unit rewards will be halved(0) 讚! | 润发大叔 |
作者: 润发大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-10-29 11:55:44 評論於 Review Speed: 2.0 | Submission Acceptance Rate: 50.0 Experience Sharing: After half a year, I finally hit a review article. From the email exchanges, the editor-in-chief seems nice and gave me three chances for revisions, with the last two being language-related. The language requirements were extremely strict, and it was only after getting two foreigners to proofread that it passed(0) 讚! | 润发大叔 |
作者: 润发大叔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-06-11 15:57:18 評論於 The amount of articles published in the quarterly journal is too small, making it difficult(0) 讚! | 润发大叔 |
作者: 绮丝小可爱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-12-14 16:19:34 評論於 Brother, how did it go? joycelee posted on 2017-05-09 10:27:00:1-16:submit;1-30:under review, 4-7:major; 5-9:revised, please let the results be good and bless that there is no way out(0) 讚! | 绮丝小可爱 |
作者: 千斤之枫 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-07-09 20:43:51 評論於 Is this magazine any good?(0) 讚! | 千斤之枫 |
作者: 六脉永梅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-06-27 10:55:05 評論於 Even though it was 3.5 points, it showed being expelled. A major mistake!(0) 讚! | 六脉永梅 |
作者: 重阳文景 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-01-19 16:13:12 評論於 Did you accept it later?(0) 讚! | 重阳文景 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-14 09:04:14 評論於 Crossing the hurdle, bless us with good luck! Let's exceed 2 points next year(0) 讚! | 凌霄高洁 |
作者: 宗室大荒落 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-05-09 13:52:32 評論於 Review Speed: 3.0 Experience Sharing: 1-16: submit; 1-30: under review, 4-7: major; 5-9: revised, etc. Blessings in the results, no way to refuse(0) 讚! | 宗室大荒落 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us